Would you consider changing a non-diabetic patient with obesity and a history of CAD who is on semaglutide to tirzepatide if they have not achieved their weight loss goals?  

For now, I would NOT switch a patient with any atherosclerotic cardiovascular disease from semaglutide to tirzepatide, assuming that they had a substantial response to semaglutide and was tolerating semaglutide well. The rationale is that cardiovascular event prevention would be the primary goal of ...

If they have plateaued for several months or are gaining weight, I would consider changing. However, first I would recommend a nutritional review for it is possible to overeat even with GLP-1 medications.

While we don't yet have definitive cardiovascular outcomes data for tirzepatide, emerging evidence suggests it may have a favorable cardiovascular profile. Meta-analyses from earlier SURPASS trials show promising signals compared to placebo (see Figures 2 and 3 in Sattar et al., PMID 35210595). Alth...